Cleveland, Ohio (PRWEB) June 25, 2013
AMRESCO, LLC, a VWR company and a Life Science leader in the supply and contract manufacturing of high purity biochemicals, reagents and research products, announced that it has invested in a new powder manufacturing facility to support growing global business to Diagnostic, Molecular Biology and Biopharmaceutical companies. AMRESCO’s investment is part of its ongoing strategy to help increase its customers’ operational efficiencies and profitability. Its breadth of services and manufacturing capabilities offers a strong value platform and strengthens its mission to support customers and their products.
AMRESCO’s new facility increases its powder manufacturing capacity by 150%, expanding capabilities for particle size reduction, homogenous powder blending, precision powder dosing for pouching, and tablet production. This expanded and enhanced production helps to support growing product lines such as buffer blends and dehydrated media blends.
Over 35% of AMRESCO’s customers require specific formulation needs. The additional powder manufacturing capabilities and capacity allow AMRESCO to manufacture, dose and package a wider variety of powder products with varying volumes, as well as offer customers the sensitivity and most importantly, the throughput that their product requires.
Jim Taliak, VP of Global Sales at AMRESCO states, “Our customers are challenged with speed to market, operational constraints, and lack of capital or expertise. They are focusing on activities and efforts that don’t always align with their best strategic interest. Together, we look at where they need to be, then employ our skill and capabilities to assure their success.”
For nearly four decades, AMRESCO has been serving life sciences research and commercial production customers worldwide, bringing them high purity biochemicals, custom manufacturing solutions, inno
Copyright©2012 Vocus, Inc.
All rights reserved